5.27 -0.035 (-0.66%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 7.42 | 1-year : | 8.46 |
Resists | First : | 6.35 | Second : | 7.25 |
Pivot price | 5.38 | |||
Supports | First : | 4.92 | Second : | 4.09 |
MAs | MA(5) : | 5.21 | MA(20) : | 5.76 |
MA(100) : | 7.03 | MA(250) : | 8.9 | |
MACD | MACD : | -0.4 | Signal : | -0.5 |
%K %D | K(14,3) : | 17.7 | D(3) : | 13.6 |
RSI | RSI(14): 38.5 | |||
52-week | High : | 23.38 | Low : | 4.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OBIO ] has closed above bottom band by 39.7%. Bollinger Bands are 59.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 5.63 - 5.66 | 5.66 - 5.69 |
Low: | 5.11 - 5.14 | 5.14 - 5.17 |
Close: | 5.22 - 5.28 | 5.28 - 5.32 |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Fri, 29 Mar 2024
Orchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Fri, 29 Mar 2024
Orchestra BioMed (NASDAQ:OBIO) Given “Buy” Rating at Chardan Capital - Defense World
Thu, 28 Mar 2024
Orchestra BioMed (NASDAQ:OBIO) Given "Buy" Rating at Chardan Capital - MarketBeat
Wed, 27 Mar 2024
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update - GlobeNewswire
Tue, 26 Mar 2024
Orchestra BioMed adds David Pacitti to Board of Directors - Investing.com South Africa
Tue, 26 Mar 2024
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 36 (M) |
Held by Insiders | 1.942e+007 (%) |
Held by Institutions | 37.2 (%) |
Shares Short | 1,050 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.857e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 466.3 % |
Return on Equity (ttm) | -27.2 % |
Qtrly Rev. Growth | 3.6e+006 % |
Gross Profit (p.s.) | -355.56 |
Sales Per Share | -362.67 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -44 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.02 |
Price to Cash Flow | 0.42 |
Dividend | 0 |
Forward Dividend | 987100 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |